时间标签：数据日期 2026-11-01 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31–2026/11/01 ｜ 情报发生日期 2026-11-01
研究问题
Of note, a substantial proportion of individuals with MASLD have obesity, and individuals with obesity typically have greater absolute MS and MM but poorer PP than those without obesity [ , , , ].；Therefore, evaluating muscle health in individuals with MASLD without considering obesity status may
方法
Given that most UK Biobank participants were White, we performed a sensitivity analysis restricted to White participants to minimize bias due to population stratification.；All statistical analyses were two‐tailed and performed using R statistical software version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria). 4.6 Secondary Analyses We performed subgroup analyses stratified by sex (male and…；To further evaluate the external generalizability of our findings, we conducted an independent external validation using the United States National Health and Nutrition Examination Survey (NHANES) 2011–2018.
核心结论
In participants with MASLD, a decrease in handgrip strength was significantly associated with an increased risk of CVD [ ].；For instance, data from the UK Biobank showed that faster walking speed, whether self‐reported or objectively measured, was associated with a reduced risk of cancer development in the general population [ , ].；Despite smaller sample sizes, low MM was also consistently associated with increased risks, particularly for cirrhosis, HCC, CKD, and all‐cause mortality (Table ).；This is also in line with prior studies showing that lean MASLD with sarcopenia is associated with increased risks of CVD and advanced fibrosis [ , ].；conclusion, our findings emphasize coexisting of MASLD and sarcopenia‐related abnormalities was associated with a substantially higher risk of both liver‐related and extrahepatic outcomes, particularly in obese participants.
局限
Given that most UK Biobank participants were White, we performed a sensitivity analysis restricted to White participants to minimize bias due to population stratification.；Third, interventions such as lifestyle modification, nutritional supplementation, resistance training, and emerging pharmacological therapies targeting sarcopenic obesity warrant further investigation in this high‐risk population.
对本项目的价值
人群纵向证据，可用于假说生成与终点选择：代谢—器官轴是干预安全性的主要约束面。 ｜ 价值分 1.0/5（★☆☆☆☆）
全文来源
PubMed PMC JATS 全文（正文 28,473 字符，已过 DOI 逐字 + 题名指纹双重归属校验）
原文题录
- 英文标题：Associations of Coexisting Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia-Related Abnormalities With Adverse Clinical Outcomes Across Obesity States.
- 期刊与标识：MedComm · PMID 42960301 · DOI 10.1002/mco2.71111
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。